Earnings are out
NEUP · NASDAQ · Biotechnology

Neuphoria Therapeutics (NEUP)

Develops BNC210 for anxiety and trauma-related disorders through virtualized clinical development.

$3.75
At close−0.04 (−1.06%)

Something off on this page? Send us feedback.

Next report
Oct 5, 2026
estimated · in 32 days
EPS estimate
−$1.58
Revenue estimate
Fiscal quarter
Q1 FY27

EPSReportedEstimate

Mar '25May '25Sep '25Nov '25Feb '26May '26Sep '26Oct '26
Reported−$0.01$6.55−$5.79−$4.41−$0.77−$0.09−$0.56Pending
Estimate−$2.01−$0.47−$0.56−$0.55−$0.56−$0.56−$0.56−$1.58
Surprise+99.6%+1,493.6%−933.9%−701.8%−37.5%+83.9%0.0%

RevenueReportedEstimate

Mar '25May '25Sep '25Nov '25Feb '26May '26Sep '26Oct '26
Reported$662.6K$15.0M−$15.7MPending
Estimate$264.3K$264.3K$264.3K
Surprise+150.7%+5,575.4%−6,026.1%

History

DateEstimateReportedSurprise
Oct 2026−$1.58
Sep 2026−$0.56−$0.560.0%
May 2026−$0.56−$0.09+83.9%
Feb 2026−$0.56−$0.77−37.5%
Nov 2025−$0.55−$4.41−701.8%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Sep 2025
May 2025
Mar 2025
Nov 2024
Sep 2024
Mar 2024
Dec 2023
Sep 2023
Feb 2023
Aug 2022
Feb 2022
Aug 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Oct 5, 2026−$1.58
Sep 2, 2026−$0.56−$0.560.0%−1.1%
May 15, 2026−$0.56−$0.09+83.9%−0.2%
Feb 17, 2026−$0.56−$0.77−37.5%+8.9%
Nov 14, 2025−$0.55−$4.41−701.8%−1.9%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Sep 29, 2025
May 20, 2025
Mar 17, 2025
Nov 15, 2024
Sep 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Feb 23, 2023
Aug 25, 2022
Feb 23, 2022
Aug 25, 2021$3.5M